ATAndreas Topp

Andreas Topp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreas Topp has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Walter

    Pharma Research & Early Development (pRED) F. Hoffmann-La Roche Ltd Grenzacherstrasse 124 CH-4070 Basel CH

    2 shared publications
  • Axel Hentsch

    Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Roessle-Strasse 10 13125 Berlin GER

    2 shared publications
  • Bernd Kuhn

    Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel F. Hoffmann‐La Roche AG Basel 4070 Switzerland

    2 shared publications
  • Dominik Heer

    Pharma Research & Early Development (pRED) F. Hoffmann-La Roche Ltd Grenzacherstrasse 124 CH-4070 Basel CH

    2 shared publications
  • Jens Peter von Kries

    Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Roessle-Strasse 10 13125 Berlin GER

    2 shared publications
  • Jerome Paul

    Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Roessle-Strasse 10 13125 Berlin GER

    2 shared publications

Latest Publications

  • Evaluating the workload impact of a Rotary talent management strategy on engineering change administration across automotive manufacturing divisions

    by Álvaro A. Castillo-Paz, Armando Elizondo-Noriega, Gareth Emmett, Andreas Topp, Jennifer Rouen, Roberto Liñan, Alan S. Pérez, Rodrigo Cervantes, Adolfo Ramirez, Adrián Benavides, et al.

  • Open Access

    A Highly Selective and Versatile Probe Platform for Visualization of Monoacylglycerol Lipase

    by Axel Hentsch, Mónica Guberman, Silke Radetzki, Sofia Kaushik, Mirjam Huizenga, Jerome Paul, Maria Schippers, Jörg Benz, Bernd Kuhn, Dominik Heer, et al.

    Monoacylglycerol lipase (MAGL) is a key enzyme for signal termination in the endocannabinoid system (ECS). MAGL inhibition results in indirect activation of the cannabinoid receptors, which offers unique advantages for the treatment of, e.g., multiple sclerosis, epilepsy, and other neurological disorders. Molecular imaging techniques are valuable tools to overcome the current poor understanding of MAGL's distribution and role in patho‐ and physiological processes within ECS signaling. Herein, we report the design, synthesis, and validation of highly selective versatile fluorescent and click‐chemistry probes for MAGL. Structure‐based design combined with a reverse‐design approach allowed the development of a structural unit that selectively and effectively recognizes MAGL while offering a versatile platform to attach different fluorophores and further reporter units. In this way, labeled probes with sub‐nanomolar potency carrying diverse fluorescent dyes were obtained. Probe affinity and selectivity remained invariant to changes in the fluorophore subunit, showing the remarkable robustness of this platform in delivering tailor‐made probes. Highly consistent inhibition across species supports pharmacological model translatability. Extensive profiling and validation in various cellular systems shows the ability of these highly potent and selective probes to elucidate the complex role of MAGL in ECS cellular signaling, inflammatory processes, and disease progression.

  • Open Access

    A Highly Selective and Versatile Probe Platform for Visualization of Monoacylglycerol Lipase

    by Axel Hentsch, Mónica Guberman, Silke Radetzki, Sofia Kaushik, Mirjam Huizenga, Jerome Paul, Maria Schippers, Jörg Benz, Bernd Kuhn, Dominik Heer, et al.

    Monoacylglycerol lipase (MAGL) is a key enzyme for signal termination in the endocannabinoid system (ECS). MAGL inhibition results in indirect activation of the cannabinoid receptors, which offers unique advantages for the treatment of, e.g., multiple sclerosis, epilepsy, and other neurological disorders. Molecular imaging techniques are valuable tools to overcome the current poor understanding of MAGL's distribution and role in patho‐ and physiological processes within ECS signaling. Herein, we report the design, synthesis, and validation of highly selective versatile fluorescent and click‐chemistry probes for MAGL. Structure‐based design combined with a reverse‐design approach allowed the development of a structural unit that selectively and effectively recognizes MAGL while offering a versatile platform to attach different fluorophores and further reporter units. In this way, labeled probes with sub‐nanomolar potency carrying diverse fluorescent dyes were obtained. Probe affinity and selectivity remained invariant to changes in the fluorophore subunit, showing the remarkable robustness of this platform in delivering tailor‐made probes. Highly consistent inhibition across species supports pharmacological model translatability. Extensive profiling and validation in various cellular systems shows the ability of these highly potent and selective probes to elucidate the complex role of MAGL in ECS cellular signaling, inflammatory processes, and disease progression.


  • Novel β‐Glucocerebrosidase Activators That Bind to a New Pocket at a Dimer Interface and Induce Dimerization

    by Joerg Benz, Arne C. Rufer, Sylwia Huber, Andreas Ehler, Melanie Hug, Andreas Topp, Wolfgang Guba, Eva Carolina Hofmann, Ravi Jagasia, Rosa María Rodríguez Sarmiento

    Genetic, preclinical and clinical data link Parkinson's disease and Gaucher's disease and provide a rational entry point to disease modification therapy via enhancement of β‐Glucocerebrosidase (GCase) activity. We discovered a new class of pyrrolo[2,3‐b]pyrazine activators effecting both Vmax and Km. They bind to human GCase and increase substrate metabolism in the lysosome in a cellular assay. We obtained the first crystal structure for an activator and identified a novel non‐inhibitory binding mode at the interface of a dimer, rationalizing the observed structure–activity relationship (SAR). The compound binds GCase inducing formation of a dimeric state at both endoplasmic reticulum (ER) and lysosomal pHs, as confirmed by analytical ultracentrifugation. Importantly, the pyrrolo[2,3‐b]pyrazines have central nervous system (CNS) drug‐like properties. Our findings are important for future drug discovery efforts in the field of GCase activation and provide a deeper mechanistic understanding of the requirements for enzymatic activation, pointing to the relevance of dimerization.